This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the University of Massachusetts Medical School (UMass Medical) provides $196,029 to conduct research focused on understanding the immune evasion mechanisms associated with mutant IDH1 cancer.
The key objectives of the project are to: 1) decipher the role of viral mimicry in the response to IDH1 inhibition, and 2) explore the contribution of metabolic crosstalk to immune evasion in IDH1 mutant cancers. This research aims to elucidate the biology of the IDH1 oncogene and uncover novel insights that could lead to the development of more effective therapeutic strategies. The project will be performed over a 3-year period from April 1, 2025 to March 31, 2028.
Generated 3/25/25, 3:34 AM